Phase 1 × Completed × Lymphoma, B-Cell, Marginal Zone × Clear all Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
Phase 1 Completed
35 enrolled
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
Phase 1 Completed
50 enrolled
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Phase 1 Completed
26 enrolled
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Phase 1 Completed
50 enrolled
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
Phase 1 Completed
8 enrolled
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Phase 1 Completed
11 enrolled 16 charts
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
Phase 1 Completed
14 enrolled
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
Phase 1 Completed
154 enrolled
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Phase 1 Completed
18 enrolled
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
Phase 1 Completed
43 enrolled
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Phase 1 Completed
132 enrolled
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors
Phase 1 Completed
3 enrolled
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
Phase 1 Completed
91 enrolled
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Phase 1 Completed
16 enrolled
A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)
Phase 1 Completed
17 enrolled
Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Completed
35 enrolled
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
Phase 1 Completed
32 enrolled 30 charts
BRiM
Phase 1 Completed
11 enrolled 20 charts
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
Phase 1 Completed
39 enrolled
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Phase 1 Completed
18 enrolled
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
Phase 1 Completed
6 enrolled 14 charts
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Phase 1 Completed
55 enrolled
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies
Phase 1 Completed
29 enrolled
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
Phase 1 Completed
Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma
Phase 1 Completed
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
Phase 1 Completed
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma
Phase 1 Completed
26 enrolled
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 Completed
2 enrolled
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Phase 1 Completed
20 enrolled
Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
Phase 1 Completed
34 enrolled
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Phase 1 Completed
70 enrolled
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
Phase 1 Completed
44 enrolled
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 1 Completed
18 enrolled
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase 1 Completed
34 enrolled
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
Phase 1 Completed
90 enrolled
DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma
Phase 1 Completed
25 enrolled
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies
Phase 1 Completed
86 enrolled
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
Phase 1 Completed
17 enrolled
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase 1 Completed
29 enrolled
A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma
Phase 1 Completed
12 enrolled 15 charts
Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
Phase 1 Completed
26 enrolled
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Phase 1 Completed
46 enrolled 11 charts
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
Phase 1 Completed
20 enrolled
Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy
Phase 1 Completed
89 enrolled
SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma
Phase 1 Completed
20 enrolled
VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Completed
VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Completed
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Completed
25 enrolled
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Completed
25 enrolled
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Phase 1 Completed
27 enrolled